Daily Cardiology Research Analysis
Analyzed 140 papers and selected 3 impactful papers.
Summary
Three impactful cardiology studies stand out today: an individual patient data meta-analysis identifies echocardiographic combinations that better predict short-term mortality in acute pulmonary embolism; metabolomics within the PREDIMED trial links a urinary polyphenol signature of Mediterranean diet adherence to lower cardiovascular disease risk; and the 2025 ACC/AHA/HRS/ISACHD/SCAI guideline updates comprehensive management for adults with congenital heart disease.
Research Themes
- Risk stratification in acute pulmonary embolism using echocardiography
- Metabolomics biomarkers of Mediterranean diet adherence and CVD prevention
- Guideline-driven care in adult congenital heart disease
Selected Articles
1. Right Ventricular Dysfunction at echocardiography to Predict Mortality in Acute Pulmonary Embolism: an IPDMA.
Across 9,233 acute PE patients, multiple echocardiographic markers of right ventricular dysfunction (e.g., TAPSE <16 mm, RV/LV >1) were associated with higher 30-day mortality. A single abnormal parameter was insufficient, whereas two or more abnormalities substantially increased risk, supporting a combinatorial approach to echo-based risk stratification.
Impact: This IPD meta-analysis provides robust, practice-ready evidence that combinations of echo parameters outperform single metrics for short-term mortality prediction in PE.
Clinical Implications: In acute PE, consider requiring ≥2 abnormal RVD parameters (e.g., low TAPSE plus RV/LV >1) to upstage risk and guide escalation of monitoring or therapy. This supports targeted use of reperfusion strategies and ICU-level care in high-risk subsets.
Key Findings
- In 9,233 PE patients, 30-day mortality was 7%; multiple RVD markers (TAPSE<16 mm, PAP>30 mmHg, RV/LV>1, RV hypokinesis, paradoxical septal motion, dilated RV) were associated with death.
- One abnormal RVD parameter was not associated with increased short-term mortality (OR 1.17), but two (OR 1.52) or ≥3 (OR 2.33) abnormalities were.
- The combination of RV/LV>1 and TAPSE<16 mm showed stronger association with death than either alone (OR 2.49).
Methodological Strengths
- Individual patient data meta-analysis with large sample size (n=9,233)
- Assessment of both individual and combined echocardiographic RVD parameters with clinically relevant 30-day outcomes
Limitations
- Potential heterogeneity in echocardiographic acquisition and interpretation across included studies
- Observational nature of source datasets may introduce residual confounding
Future Directions: Prospective validation of a combinatorial RVD score and integration with biomarkers/CT metrics to refine PE risk stratification and therapeutic decision thresholds.
BACKGROUND: In patients with acute pulmonary embolism (PE), echocardiography is currently used to detect right ventricular dysfunction (RVD) and guide risk stratification and treatment decisions. However, the prognostic value of individual parameters of RVD at echocardiography and of their combinations remains uncertain. OBJECTIVES: To assess the association between individual parameters of RVD at echocardiography and short-term all-cause and PE-related death, and to evaluate whether combinations of parameters improve risk stratification. METHODS: We performed an individual patient data meta-analysis (IPDMA) of studies reporting on echocardiography findings and 30-day mortality in patients with acute PE. Outcomes included short-term all-cause and PE-related death. RESULTS: Overall, 9,233 patients were included, having 7% (95% CI 6-9) rate of short-term death. Tricuspid annular plane systolic excursion (TAPSE)<16mm, estimated pulmonary artery pressure (PAP)>30mmHg, right-to-left ventricle diameter (RV-to-LV) ratio>1, RV hypokinesis, paradoxical septal motion, and dilated RV were associated with short-term death and PE-related death at univariate analyses. Among 8,905 patients with at least three RVD parameters assessed, having one single abnormal parameter was not associated with short-term death (OR 1.17, 95% CI 0.92-1.47), while having two (OR 1.52, 95% CI 1.19-1.54) or three or more parameters was (OR 2.33, 95% CI 1.79-3.03). Among couples of parameters, a trend toward increasing association with death was observed for the combination of RV-to-LV>1 and TAPSE<16 mm (OR 2.49, 95% CI: 1.23-5.01), compared to either parameter alone. CONCLUSION: In acute PE patients, RVD parameters at echocardiography are associated with all-cause and PE-related death. The combination of at least two RVD parameters identifies PE patients at increased risk for death.
2. Urinary polyphenol signature of the Mediterranean diet is associated with lower cardiovascular disease risk: the PREDIMED trial.
In a nested case-cohort within PREDIMED (n=1,180), an eight-metabolite urinary phenolic signature of Mediterranean diet adherence predicted lower incident CVD in a dose–response manner. MedDiet interventions increased walnut-derived urolithin A, supporting biological plausibility of polyphenol-mediated cardioprotection.
Impact: Provides an objective biomarker panel for dietary adherence linked prospectively to lower CVD risk, moving beyond self-report and enabling precision nutrition strategies.
Clinical Implications: Urinary phenolic metabolite profiling could monitor and personalize Mediterranean diet interventions in preventive cardiology, with emphasis on polyphenol-rich foods (virgin olive oil, nuts, fruits/vegetables).
Key Findings
- An 8-metabolite urinary phenolic signature was inversely associated with incident CVD (HR per SD 0.80; Q4 vs Q1 HR 0.48; p-trend=0.002).
- Signature metabolites traced to hallmark Mediterranean foods (virgin olive oil, wine, nuts, fruits, vegetables).
- MedDiet interventions increased urolithin A metabolites at 1 year versus control, supporting causal pathways.
Methodological Strengths
- Nested case-cohort within a large randomized dietary trial with metabolomics (LC-HRMS) at baseline and 1 year
- Elastic net model for feature selection with multivariable Cox modeling and dose–response assessment
Limitations
- Case-cohort design may be susceptible to residual confounding despite adjustment
- Spot urine sampling and a predefined metabolite panel may miss temporal variability or unmeasured phenolics
Future Directions: Validate the signature in diverse populations and test biomarker-guided dietary interventions to reduce CVD events in randomized settings.
BACKGROUND: The Mediterranean diet (MedDiet) is strongly associated with lower cardiovascular disease (CVD) risk and is particularly rich in polyphenols, bioactive compounds with potential cardioprotective effects. However, the specific phenolic compounds underlying these benefits remain unclear. The objective of this study was to develop a urinary multi-metabolite signature of phenolic compounds reflecting MedDiet adherence and to evaluate its prospective association with CVD risk. METHODS: In a case-cohort nested study within the PREDIMED trial, we measured 62 phenolic metabolites in spot urine by liquid chromatography-high-resolution mass spectrometry at baseline and after 1 year in 1180 individuals: 653 incident CVD cases (stroke, myocardial infarction, CVD death, or heart failure) and a random subcohort of 603 participants (76 overlapping cases). We applied elastic net regression to derive a urinary multi-metabolite signature prospectively associated with MedDiet adherence, measured by the validated 14-item Mediterranean Diet Adherence Screener (MEDAS). Multivariable Cox models were used to estimate hazard ratios (HRs) of CVD by levels of the multi-metabolite signature. RESULTS: The urinary multi-metabolite signature, comprising eight phenolic compounds selected by elastic net regression, was inversely associated with CVD risk in a dose-response pattern (HR per SD = 0.80 (0.68-0.94); HR Q4 vs Q1 = 0.48 (0.30-0.78); p-trend = 0.002). The metabolites included in the signature were derived from foods typical of the MedDiet, particularly virgin olive oil, wine, nuts, fruits, and vegetables. After 1 year, MedDiet interventions significantly increased urolithin A metabolites (derived from walnuts) compared to the control group. CONCLUSIONS: We identified a urinary multi-metabolite signature of MedDiet adherence that is prospectively associated with lower CVD incidence. These findings support that polyphenols derived from the MedDiet showed inverse associations with cardiovascular outcomes. TRIAL REGISTRATION: The study was registered with the International Standard Randomized Controlled Trial Number (ISRCTN) 35739639.
3. 2025 ACC/AHA/HRS/ISACHD/SCAI Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
This multi-society guideline updates ACHD evaluation and management recommendations based on evidence since 2018, addressing diagnostics, longitudinal care, and interventional/surgical strategies for adult congenital lesions.
Impact: ACHD prevalence and complexity are rising; updated, consensus-based guidance will immediately shape practice, referral pathways, and resource allocation.
Clinical Implications: Clinicians should adopt updated recommendations for diagnostic imaging, risk stratification, pregnancy counseling, arrhythmia management, and timing/choice of transcatheter vs surgical interventions in ACHD.
Key Findings
- Comprehensive update of 2018 ACHD recommendations based on literature (2017–2024) across diagnostics and therapeutics.
- Emphasis on structured lifelong care and multidisciplinary coordination for complex ACHD.
- Integration of evolving interventional/surgical approaches and refined risk stratification.
Methodological Strengths
- Systematic, multi-database literature synthesis with multidisciplinary expert consensus
- Updates anchored in graded evidence and broad stakeholder societies
Limitations
- Guideline recommendations rely partly on lower-level evidence in rare/complex conditions
- Applicability may vary by regional resources and expertise
Future Directions: Promote registries and pragmatic trials in ACHD to upgrade evidence levels; evaluate implementation strategies and outcomes across diverse care settings.
AIM: The "2025 ACC/AHA/HRS/ISACHD/SCAI Guideline for the Management of Adults With Congenital Heart Disease" provides recommendations to guide clinicians on the evaluation and treatment of adult patients with congenital heart disease. It incorporates new evidence to replace the "2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease." METHODS: A comprehensive literature search was conducted with a focus on literature published from 2017 to 2024; in some instances, older literature was also collected and reviewed. Clinical studies, systematic reviews and meta-analyses, and other evidence conducted on human participants and published in English were identified from MEDLINE (via PubMed), EMBASE, the Cochrane Library, Agency for Healthcare Research and Quality, and CINAHL for selected searches. STRUCTURE: Recommendations from the "2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease" have been updated with new evidence to guide clinicians.